Trials / Completed
CompletedNCT00780910
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-424 | 750 mg every 8 hours for 12 weeks |
| DRUG | Ribavirin | 600 - 1000 mg/day based on body weight for 24 weeks |
| DRUG | Peginterferon Alfa-2b | 1.5 mcg/kg/week for 24 weeks |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2008-10-28
- Last updated
- 2026-01-06
- Results posted
- 2012-08-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00780910. Inclusion in this directory is not an endorsement.